Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : BIOPOOL(BIPL) -- Ignore unavailable to you. Want to Upgrade?

To: Dave B who wrote (363)	3/31/1998 9:27:00 AM
From: Billie Thon	Read Replies (1) \| Respond to of 507

News! Tuesday March 31, 6:32 am Eastern Time Company Press Release Biopool International Receives Regulatory Agency Approval to Market 11 Products in France VENTURA, Calif.--(BUSINESS WIRE)--March 31, 1998--Biopool International, Inc. (Nasdaq:BIPL - news) today announced that the Company has received approval from the French regulatory agency, l'Agence du Medicament (''ADM''), to market 11 of its immunohematology products in France. The registration of these products is a key first step in an effort to more effectively market the Company's product line in France. Michael D. Bick, Ph.D., chairman and chief executive officer of Biopool, commented, ''This is just the first step in a much larger project to establish Biopool's market presence in France and other key countries of Europe. These first 11 approvals reflect a transition of products currently distributed by Organon Teknika France to the Biopool brand name. We also have another 30 immunohematology products pending registration with the ADM, most of which represent first-time registrations. In addition, we have submitted first-time registration files for over 30 hemostasis products with the ADM over the past six months and expect to begin receiving market approvals within the next two to three months.'' In conjunction with these efforts, Biopool has registered a local sales office in France, ''Biopool France,'' and will begin direct sales activities as additional product market approvals are received from the ADM. Dr. Bick continued, ''While we currently derive some 23% of our total sales revenues from Europe, we have yet to establish what could be considered a ''significant presence'' in any European country. We are first focusing on building our business in France because it is the second largest market by population and the largest market for per capita spending on immunohematology products within the European Union. Also, historically, many innovative products in both immunohematology and hemostasis have been developed in France, and our commitment to grow our business there has opened the door for Biopool to explore certain collaborative relationships, which can have a positive impact on our future growth.'' Founded in 1987, Biopool International develops, manufactures, and markets a full range of test kits to assess and diagnose disorders of blood coagulation, thrombotic risk factors, fibrinolysis, platelet function, and the vascular system; specialty chemistry controls used to monitor and measure the presence of drugs of abuse; and blood group serology products used to screen for antibodies and group and type whole blood. The Company's product line of over 150 FDA-approved products is sold to hospitals, blood bank facilities, and clinical and reference laboratories on a worldwide basis by the Company's own sales representatives, as well as through an extensive network of distributors. NOTE: This press release contains forward-looking statements regarding the Company's future market presence in France and growth potential offered by possible collaborative relationships which are based upon current expectations that involve a number of risks and uncertainties including, but not limited to, technological innovations of competitors, changes in health care regulations, litigation claims, foreign currency fluctuation, product acceptance or changes in government regulation of the Company's products, as well as other factors discussed in the Company's last Report on Form 10-K-SB under ''Risk Factors.'' Contact: Biopool International, Inc. Michael D. Bick or Carol Hill, 805/654-0643